Vyvgart Hytrulo Purple Book BLA 761304
- BLA number
- 761304
- Proprietary names
- Vyvgart Hytrulo
- Proper names
- efgartigimod alfa and hyaluronidase-qvfc
- Applicant
- Argenx BV
- Center
- CDER
- First observed release
- 2023-06-01
- Latest observed release
- 2026-06-01
- Newest archive release
- 2026-06-01
- FDA patent list
- No patents listed in the captured FDA patent list; source updated 2025-06-11
- Coverage
- Present in newest release
Latest Known Product Presentations#
Product, Proprietary name, Proper name table| Product | Proprietary name | Proper name | License type | Strength | Dosage form | Route | Presentation | Marketing | Licensure | Approval | Patent list provided |
|---|
| 001 | Vyvgart Hytrulo | efgartigimod alfa and hyaluronidase-qvfc | 351(a) | 1,008MG/5.6ML; 11,200UNITS/5.6ML (180MG/2,000UNITS/ML) | Injection | Subcutaneous | Single-Dose Vial | Rx | Licensed | 2023-06-20 | |
| 002 | Vyvgart Hytrulo | efgartigimod alfa and hyaluronidase-qvfc | 351(a) | 1,000MG/5ML;10,000UNITS/5ML (200MG/2,000UNITS/ML) | Injection | Subcutaneous | Pre-Filled Syringe | Rx | Licensed | 2025-04-10 | |
Published Patent List#
No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.
Official Monthly Change Events#
Release, Event, Product table| Release | Event | Product | Name | License type | Status | Applicant |
|---|
| 2025-05-01 | N | 002 | Vyvgart Hytrulo | 351(a) | Rx | Argenx BV |
| 2024-08-01 | U | 001 | Vyvgart Hytrulo | 351(a) | Rx | Argenx BV |
| 2023-11-01 | U | 001 | Vyvgart Hytrulo | 351(a) | Rx | Argenx BV |
| 2023-06-01 | N | 001 | Vyvgart Hytrulo | 351(a) | Rx | Argenx BV |
Observed Product State History#
Release, Product, Name table| Release | Product | Name | License type | Marketing | Licensure | Approval |
|---|
| 2025-05-01 | 002 | Vyvgart Hytrulo | 351(a) | Rx | Licensed | 2025-04-10 |
| 2023-06-01 | 001 | Vyvgart Hytrulo | 351(a) | Rx | Licensed | 2023-06-20 |